Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>Numinus extends collaboration with MAPS. Last week, Numinus announced a partnership with the Multidisciplinary Association for Psychedelic Studies (MAPS) to support psychedelic experiential opportunities for practitioners as part of a clinical study, with permission to use MAPS’ protocol for the study.</li><li>Numinus has submitted a clinical trial application (CTA) to Health Canada, which, if approved, will make the MDMA-AT experiential opportunity for practitioners available only through Numinus.</li><li>This partnership is not the first collaboration between Numinus and MAPS and highlights the strong relationship and trust between the two.</li></ul>

Numinus extends collaboration with MAPS. Last week, Numinus announced a partnership with the Multidisciplinary Association for Psychedelic Studies (MAPS) to support psychedelic experiential opportunities for practitioners as part of a clinical study, with permission to use MAPS’ protocol for the study.Numinus has submitted a clinical trial application (CTA) to Health Canada, which, if approved, will make the MDMA-AT experiential opportunity for practitioners available only through Numinus.This partnership is not the first collaboration between Numinus and MAPS and highlights the strong relationship and trust between the two.

Numinus Wellness, Inc. - In the Driver's Seat for Prospective Rollout of MDMA-AT